GC Cell has signed a memorandum of understanding (MOU) with PT Bifarma Adiluhung to introduce Immuncell-LC, an autologous T-cell therapy for hepatocellular carcinoma (HCC), to the Indonesian healthcare market.

The strategic deal between the two companies facilitates the entry of the therapy into the country, thereby expanding its reach.

Immuncell-LC is the only approved treatment for liver cancer in Korea.

The deal encompasses not only the introduction of Immuncell-LC in Indonesia but also talks on technology transfer and the joint development of further natural killer (NK) cell therapy pipelines.

GC Cell recently launched its Blueprint 2.0 strategy, which underscores a strategic shift towards developing future growth drivers, including the global commercialisation of its cell therapy products.

Immuncell-LC is at the forefront of this global expansion, especially in Asia-Pacific.

GC Cell CEO James Park stated: “This partnership is a testament to the global recognition of our cell therapy expertise, first established in Korea.

“By combining GC Cell’s integrated value chain in cell and gene therapy with Bifarma’s strong market presence and capabilities in Indonesia, we are poised to rapidly capture a leading position in the burgeoning field of anti-cancer cell therapies.”

GC Cell intends to leverage the wide-ranging infrastructure of the Kalbe Group in the region. The group comprises cold chain logistics and an extensive hospital network, which can expedite the introduction of Immuncell-LC beyond the Korean market.

PT Bifarma Adiluhung president director Dr Sandy Qlintang stated: “We are pleased to announce that Bifarma, through our cell therapy division ReGeniC, has entered into a MOU with GC Cell, a pioneering biopharmaceutical company from Korea.

“The strategic collaboration represents a significant milestone for both organisations and reinforces our mission to offer advanced, safe and high-quality cell therapy.”